<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Medical Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/medicine-technology-1/</link>
<description>Latest Medical Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2007. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/UNT-Health-Science-Centers-Groundbreaking-Research-Applied-to-Protecting-Brain-After-Traumatic-Injury-4679-1/</link>
<pubDate>Fri, 03 Jul 2009 09:15:48 MST</pubDate>
<description><![CDATA[FORT WORTH, Texas, July 3 /PRNewswire-USNewswire/ -- In groundbreaking research, scientists at the University of   North Texas Health Science Center at Fort Worth   have determined that rapid estrogen administration can protect the brain following brain injury. These findings are now being tested on human trauma patients in North Texas.          James Simpkins  , Ph.D., UNT Health Science Ce... ]]></description>
</item>
<item>
<title><![CDATA[BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/BioCis-Pharma-Reports-Positive-Phase-IIa-Clinical-Results-in-Atopic-Dermatitis-4678-1/</link>
<pubDate>Fri, 03 Jul 2009 05:07:28 MST</pubDate>
<description><![CDATA[TURKU, Finland, July 3 /- BioCis Pharma Ltd., a privately  held drug development company with its headquarters in Turku, Finland,  announced positive results from its Phase IIa clinical trial of ProtoCure(TM)  emulsion cream, the company's novel topical drug for dermatology. This  double-blind, placebo-controlled study, conducted in Finland, included 13  patients with mild t... ]]></description>
</item>
<item>
<title><![CDATA[ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/ThromboGenics-and-BioInvent-Start-Recruitment-of-Second-100-Patient-Cohort-in-Phase-II-DVT-Prophylaxis-Study-With-TB-402-4677-1/</link>
<pubDate>Thu, 02 Jul 2009 10:36:04 MST</pubDate>
<description><![CDATA[LEUVEN, Belgium and LUND, Sweden, July 3 /-  ThromboGenics NV (Euronext Brussels: THR) and co-development partner  BioInvent International (OMXS: BINV) announce that they have started  recruitment of a second cohort of patients for their Phase II trial of  TB-402. This follows completion of recruitment of the first cohort of 100  patients ahead of schedule. TB-402... ]]></description>
</item>
<item>
<title><![CDATA[Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Acura-and-King-Receive-FDA-Complete-Response-Letter-Regarding-Acurox-28R-29-4676-1/</link>
<pubDate>Thu, 02 Jul 2009 04:46:50 MST</pubDate>
<description><![CDATA[PALATINE, Ill. and BRISTOL, Tenn., July 2 /- Acura Pharmaceuticals, Inc. (Nasdaq:   ACUR ) and King Pharmaceuticals, Inc. (NYSE:   KG ) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product i... ]]></description>
</item>
<item>
<title><![CDATA[Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Current-Status-of-the-Development-Programs-of-New-Indications-and-Formulations-for-Aricept-28R-29-for-Enhancing-Patient-Value-4675-1/</link>
<pubDate>Thu, 02 Jul 2009 03:42:41 MST</pubDate>
<description><![CDATA[TOKYO and WOODCLIFF LAKE, N.J., July 2 /- Eisai Co., Ltd. (Headquarters: Tokyo, President &amp; CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further c... ]]></description>
</item>
<item>
<title><![CDATA[deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/deCODE-led-Megastudy-Finds-New-Genetic-Clues-to-Causes-of-Schizophrenia-4674-1/</link>
<pubDate>Wed, 01 Jul 2009 10:35:14 MST</pubDate>
<description><![CDATA[REYKJAVIK, Iceland, July 1 /- The largest study of  the genetics of schizophrenia ever undertaken has revealed several new common  single-letter variants in the sequence of the human genome (SNPs) linked to  risk of the disease. The study, by a multinational consortium of scientists  led by a team from deCODE genetics (Nasdaq:  DCGN ), analyzed the genomes of  more... ]]></description>
</item>
<item>
<title><![CDATA[New Review on PROSTVAC(TM) Published by Key Investigators From NCI]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Review-on-PROSTVAC-28TM-29-Published-by-Key-Investigators-From-NCI-4673-1/</link>
<pubDate>Wed, 01 Jul 2009 07:56:38 MST</pubDate>
<description><![CDATA[KVISTGAARD, Denmark, July 1 /- A just published  Review in the publication "Expert Opinion on Investigational Drugs", Volume  18, Issue 7 2009, confirms the previous published information on  PROSTVAC(TM). This is the most comprehensive and updated Review on  PROSTVAC(TM) so far.          Quote from the article: "Preliminary clinical trials have indicated  negligib... ]]></description>
</item>
<item>
<title><![CDATA[Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Keep-Mosquitoes-and-More-Out-of-Your-Yard-with-Garlic-From-Garlic-Research-Labs--Inc--4672-1/</link>
<pubDate>Tue, 30 Jun 2009 03:07:14 MST</pubDate>
<description><![CDATA[GLENDALE, Calif., June 30 /- If you have been eating Garlic to keep the mosquitoes away you may want to think again.  While there is absolutely no scientific evidence that eating garlic actually keeps mosquitoes away, spraying garlic has plenty of evidence to prove it keeps them away.         Spraying garlic extract on grassy lawns is not as strange as it seems. Mosquito Barrier... ]]></description>
</item>
<item>
<title><![CDATA[PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/PARI-LC-Plus-and-PRONEB-Ultra-Used-in-Two-Perforomist-Studies-on-Improving-COPD-Therapies-4671-1/</link>
<pubDate>Tue, 30 Jun 2009 10:18:21 MST</pubDate>
<description><![CDATA[MIDLOTHIAN, Va., June 30 /- In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function.         "We are pleased that researchers chose PARI products as the exclusive nebulizer systems for recent studies compa... ]]></description>
</item>
<item>
<title><![CDATA[Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Accumetrics--Inc--Announces-GRAVITAS-Trial-50-Percent-Enrolled-4670-1/</link>
<pubDate>Tue, 30 Jun 2009 07:18:16 MST</pubDate>
<description><![CDATA[SAN DIEGO, June 30 /- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS ( G auging  R esponsiveness with  A V erifyNow(R) Assay  I mpact on  T hrombosis  A nd  S afety).  The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for pat... ]]></description>
</item>
<item>
<title><![CDATA[Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Cephalon-Submits-NUVIGIL-Supplemental-New-Drug-Application-for-the-Treatment-of-Excessive-Sleepiness-Associated-with-Jet-Lag-Disorder-4669-1/</link>
<pubDate>Tue, 30 Jun 2009 05:26:42 MST</pubDate>
<description><![CDATA[FRAZER, Pa., June 30 /- Cephalon, Inc. (Nasdaq:   CEPH ) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting... ]]></description>
</item>
<item>
<title><![CDATA[Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Calixa-Therapeutics-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Its-Antibiotic--CXA-101--in-Patients-with-Complicated-Urinary-Tract-Infections-4668-1/</link>
<pubDate>Tue, 30 Jun 2009 04:39:02 MST</pubDate>
<description><![CDATA[SAN DIEGO, June 30 /- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections.  CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent  in vitro  and  in vivo  activity against  Pseudomonas aeruginosa , including drug resistant isolates.  Calixa is investigat... ]]></description>
</item>
<item>
<title><![CDATA[New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Data-Supports-Significant-Economic-and-Clinical-Value-of-MENOPUR-28R-29-in-IVF-4667-1/</link>
<pubDate>Tue, 30 Jun 2009 01:50:28 MST</pubDate>
<description><![CDATA[AMSTERDAM, The Netherlands, June 30 /-          - "Study Could Have Major Impact on the Decision-Making Process With  Respect to Infertility Treatment"          New data from an economic analysis presented today at this year's  European Society of Human Reproduction and Embryology (ESHRE) congress showed  that, within the parameters of the simulation model used, the in vitro... ]]></description>
</item>
<item>
<title><![CDATA[MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/MedImmune-Funds-Study-to-Help-Gain-Insights-Into-Full-Burden-of-RSV-Disease-Among-Premature-Infants-4666-1/</link>
<pubDate>Mon, 29 Jun 2009 09:34:45 MST</pubDate>
<description><![CDATA[Prospective Study Seeks to Assess RSV Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research          GAITHERSBURG, Md., June 29 /- MedImmune continues to advance its commitment to pediatric research with today's announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus (RS... ]]></description>
</item>
<item>
<title><![CDATA[Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Mayo-Clinic-Proceedings-Reviews-Deep-Brain-Stimulation-to-Treat-Psychiatric-Diseases-4665-1/</link>
<pubDate>Mon, 29 Jun 2009 08:54:37 MST</pubDate>
<description><![CDATA[ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ --  Pioneering therapeutic trials to investigate the effectiveness of   deep brain stimulation (DBS)   in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the world, according to a review in the June 2009 issue of      Mayo Clinic Proceedings   . "Deep brain... ]]></description>
</item>
<item>
<title><![CDATA[AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/AcelRx-Announces-Positive-Phase-2-Results-from-a-Study-of-ARX-01-Sufentanil-NanoTabs-in-Treating-Post-Operative-Pain-4664-1/</link>
<pubDate>Mon, 29 Jun 2009 04:23:13 MST</pubDate>
<description><![CDATA[Study in major abdominal surgery patients achieved primary and secondary endpoints        REDWOOD CITY, Calif., June 29 /- AcelRx Pharmaceuticals, Inc. today announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs(TM) for the management of acute post-operative pain in patients requiring opioid analges... ]]></description>
</item>
<item>
<title><![CDATA[Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Pangu-BioPharma--aTyr-Pharmas-Subsidiary-in-Hong-Kong--Files-Three-Patent-Applications-4663-1/</link>
<pubDate>Mon, 29 Jun 2009 03:29:24 MST</pubDate>
<description><![CDATA[aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases         SAN DIEGO, June 29 /- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application on proprietary, naturally occurring, resected human tRNA synthetases.  Although tRNA synthetases are universal and essential components of pro... ]]></description>
</item>
<item>
<title><![CDATA[Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Vantia-Therapeutics-Lead-Candidate-VA106483-Demonstrates-Positive-Anti-diuretic-Effect-in-Phase-IIa-Trial-in-Nocturia-4662-1/</link>
<pubDate>Mon, 29 Jun 2009 02:09:52 MST</pubDate>
<description><![CDATA[SOUTHAMPTON, England, June 29 /- Vantia Therapeutics, an  emerging pharmaceutical company developing novel, small molecule drugs  targeting large, underserved medical markets, announces positive results from  a Phase IIa clinical trial of its lead development compound VA106483 for  nocturia. The trial showed that oral VA106483 was successful in producing a  predictable and s... ]]></description>
</item>
<item>
<title><![CDATA[Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Sangamo-BioSciences-Announces-Achievement-of-Key-Milestone-in-Cell-Engineering-Agreement-With-Genentech-4661-1/</link>
<pubDate>Sun, 28 Jun 2009 11:21:48 MST</pubDate>
<description><![CDATA[RICHMOND, Calif., June 29 /- Sangamo BioSciences, Inc. (Nasdaq:   SGMO ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprieta... ]]></description>
</item>
<item>
<title><![CDATA[Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Data-Demonstrates-Long-Term-Reduction-In-Seizure-Frequency-With-Novel-Once-Daily-Anti-Epileptic-Zebinix-28R-29-4660-1/</link>
<pubDate>Sun, 28 Jun 2009 11:21:44 MST</pubDate>
<description><![CDATA[S. MAMEDE DO CORONADO, Portugal, June 29 /- Data presented  today, in Budapest, demonstrated that add-on treatment with the novel,  once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted  in a marked and sustained decrease in seizure frequency over the long-term(1).          Results from the one-year extension of a pivotal Eslicarbazepine Acetate  phas... ]]></description>
</item>
</channel>
</rss>